{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T20:03:11Z","timestamp":1770062591683,"version":"3.49.0"},"reference-count":98,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>The infant and child stage is an important stage for the continuation and development of human society. The initial years of life have a lasting impact on a child's future. Children under the age of 5 have an immature immune system, especially infants and young children under 6 months of age. At this stage, the population has a low immunity to pathogen infections, making them vulnerable to bacteria and viruses. Vaccination can enhance the immunity of infants and children to specific diseases, reduce the transmission rate of infectious diseases, and promote the development of global public health. This article summarizes the current application status of Rotavirus (RV) vaccine, Hand-foot -mouth disease (HFMD) vaccine, and Pneumococcal Conjugate Vaccine (PCV) in China, as well as the research progress of clinical trial vaccine, laying a foundation for subsequent vaccine development.<\/jats:p>","DOI":"10.3389\/fped.2024.1414177","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T04:46:22Z","timestamp":1719981982000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Progress in research and development of preventive vaccines for children in China"],"prefix":"10.3389","volume":"12","author":[{"given":"XuYang","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ge","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.amepre.2006.03.012","article-title":"Priorities among effective clinical preventive services: results of a systematic review and analysis","volume":"31","author":"Maciosek","year":"2006","journal-title":"Am J Prev Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.cvfa.2019.07.001","article-title":"Herd immunity","volume":"35","author":"Smith","year":"2019","journal-title":"Vet Clin North Am Food Anim Pract"},{"key":"B3","doi-asserted-by":"publisher","first-page":"S96","DOI":"10.1093\/cid\/civ1013","article-title":"Global, regional, and national estimates of rotavirus mortality in children <5 years of age, 2000\u20132013","volume":"62","author":"Tate","year":"2016","journal-title":"Clin Infect Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e893","DOI":"10.1016\/S2214-109X(19)30207-4","article-title":"Global impact of rotavirus vaccine introduction on rotavirus hospitalisations among children under 5 years of age, 2008\u201316: findings from the global rotavirus surveillance network","volume":"7","author":"Aliabadi","year":"2019","journal-title":"Lancet Glob Health"},{"key":"B5","first-page":"408","article-title":"Hand-foot-and-mouth disease: rapid evidence review","volume":"100","author":"Saguil","year":"2019","journal-title":"Am Fam Physician"},{"key":"B6","doi-asserted-by":"publisher","first-page":"542","DOI":"10.5114\/aoms.2012.29535","article-title":"Routine infant immunization with the 7- and 13-valent pneumococcal conjugate vaccines: current perspective on reduced-dosage regimens","volume":"8","author":"Jackowska","year":"2012","journal-title":"Arch Med Sci"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.vaccine.2024.01.030","article-title":"Impact of innovative immunization strategy on PCV13 vaccination coverage among children under 5 years in Weifang city, China: a retrospective study","volume":"42","author":"Wang","year":"2024","journal-title":"Vaccine"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1080\/21645515.2018.1520583","article-title":"Rotavirus vaccine efficacy: current status and areas for improvement","volume":"15","author":"Carvalho","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"B9","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S0272-2712(18)30111-2","article-title":"Rotavirus","volume":"19","author":"Steele","year":"1999","journal-title":"Clin Lab Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1086\/595702","article-title":"Rotarix: a rotavirus vaccine for the world","volume":"48","author":"Ward","year":"2009","journal-title":"Clin Infect Dis"},{"key":"B11","year":"2023"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e2003","DOI":"10.1002\/rmv.2003","article-title":"Rotavirus: genetics, pathogenesis and vaccine advances","volume":"28","author":"Sadiq","year":"2018","journal-title":"Rev Med Virol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.meegid.2014.08.017","article-title":"Review of global rotavirus strain prevalence data from six years post vaccine licensure surveillance: is there evidence of strain selection from vaccine pressure?","volume":"28","author":"D\u00f3r\u00f3","year":"2014","journal-title":"Infect Genet Evol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.virs.2022.07.011","article-title":"Efficacy, safety and immunogenicity of hexavalent rotavirus vaccine in Chinese infants","volume":"37","author":"Wu","year":"2022","journal-title":"Virol Sin"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1080\/14760584.2020.1853532","article-title":"A review of rotavirus vaccine use in Asia and the pacific regions: challenges and future prospects","volume":"20","author":"Buchy","year":"2021","journal-title":"Expert Rev Vaccines"},{"key":"B16","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1080\/21645515.2020.1801071","article-title":"The performance of licensed rotavirus vaccines and the development of a new generation of rotavirus vaccines: a review","volume":"17","author":"Wang","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"B17","doi-asserted-by":"publisher","first-page":"8756","DOI":"10.1016\/j.vaccine.2007.10.036","article-title":"Effectiveness of Lanzhou lamb rotavirus vaccine against rotavirus gastroenteritis requiring hospitalization: a matched case-control study","volume":"25","author":"Fu","year":"2007","journal-title":"Vaccine"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e64","DOI":"10.1038\/emi.2015.64","article-title":"Effectiveness of the live attenuated rotavirus vaccine produced by a domestic manufacturer in China studied using a population-based case-control design","volume":"4","author":"Zhen","year":"2015","journal-title":"Emerg Microbes Infect"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1016\/j.vaccine.2019.03.069","article-title":"Effectiveness of Lanzhou lamb rotavirus vaccine in preventing gastroenteritis among children younger than 5\u202fyears of age","volume":"37","author":"Li","year":"2019","journal-title":"Vaccine"},{"key":"B20","doi-asserted-by":"publisher","first-page":"7393","DOI":"10.1016\/j.vaccine.2020.04.038","article-title":"Efficacy, immunogenicity and safety of a trivalent live human-lamb reassortant rotavirus vaccine (LLR3) in healthy Chinese infants: a randomized, double-blind, placebo-controlled trial","volume":"38","author":"Xia","year":"2020","journal-title":"Vaccine"},{"key":"B21","doi-asserted-by":"publisher","first-page":"7328","DOI":"10.1016\/j.vaccine.2017.03.076","article-title":"The rotavirus vaccine development pipeline","volume":"37","author":"Kirkwood","year":"2019","journal-title":"Vaccine"},{"key":"B22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa052664","article-title":"Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine","volume":"354","author":"Vesikari","year":"2006","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"532","DOI":"10.4161\/hv.6.7.11278","article-title":"Performance of rotavirus vaccines in developed and developing countries","volume":"6","author":"Jiang","year":"2010","journal-title":"Hum Vaccin"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e2021051901","DOI":"10.1542\/peds.2021-051901","article-title":"Rotavirus vaccine safety and effectiveness in infants with high-risk medical conditions","volume":"148","author":"Van Dongen","year":"2021","journal-title":"Pediatrics"},{"key":"B25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa052434","article-title":"Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis","volume":"354","author":"Ruiz-Palacios","year":"2006","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1080\/21645515.2020.1861874","article-title":"Safety and immunogenicity of a novel oral hexavalent rotavirus vaccine: a phase I clinical trial","volume":"17","author":"Wu","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"B27","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00705-017-3614-8","article-title":"Picornaviridae-the ever-growing virus family","volume":"163","author":"Zell","year":"2018","journal-title":"Arch Virol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1080\/21645515.2019.1581539","article-title":"Enterovirus A71 vaccine effectiveness in preventing enterovirus A71 infection among medically-attended hand, foot, and mouth disease cases, Beijing, China","volume":"15","author":"Wang","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"B29","doi-asserted-by":"publisher","first-page":"112","DOI":"10.24171\/j.phrp.2018.9.3.05","article-title":"Estimating the incidence of cases and deaths resulting from hand, foot and mouth disease and its related socioeconomic disease burden in Republic of Korea (2010\u20132014)","volume":"9","author":"Seo","year":"2018","journal-title":"Osong Public Health Res Perspect"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijid.2018.12.004","article-title":"Clinical and aetiological study of hand, foot and mouth disease in southern Vietnam, 2013\u20132015: inpatients and outpatients","volume":"80","author":"Hoang","year":"2019","journal-title":"Int J Infect Dis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1303224","article-title":"An inactivated enterovirus 71 vaccine in healthy children","volume":"370","author":"Li","year":"2014","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1093\/cid\/ciz1114","article-title":"Effectiveness and safety of an inactivated enterovirus 71 vaccine in children aged 6\u201371 months in a phase IV study","volume":"71","author":"Guan","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1016\/S0140-6736(13)61049-1","article-title":"Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"381","author":"Zhu","year":"2013","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1056\/NEJMoa1304923","article-title":"Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China","volume":"370","author":"Zhu","year":"2014","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/jpids\/piaa129","article-title":"Immunogenicity and safety of inactivated enterovirus 71 vaccine in children aged 36\u201371 months: a double-blind, randomized, controlled, non-inferiority phase III trial","volume":"10","author":"Zhang","year":"2021","journal-title":"J Pediatric Infect Dis Soc"},{"key":"B36","doi-asserted-by":"publisher","first-page":"24534","DOI":"10.1038\/s41598-021-03720-y","article-title":"Molecular surveillance of pneumococcal carriage following completion of immunization with the 13-valent pneumococcal conjugate vaccine administered in a 3+1 schedule","volume":"11","author":"Syrogiannopoulos","year":"2021","journal-title":"Sci Rep"},{"key":"B37","first-page":"1991","article-title":"Pneumococcal conjugate vaccine for young children","volume":"63","author":"Zimmerman","year":"2001","journal-title":"Am Fam Physician"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1128\/JCM.00054-17","article-title":"Discovery of novel pneumococcal serotype 35D, a natural WciG-deficient variant of serotype 35B","volume":"55","author":"Geno","year":"2017","journal-title":"J Clin Microbiol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S0213-005X(17)30028-9","article-title":"Update on antibiotic resistance in gram-positive bacteria","volume":"35","author":"Lozano","year":"2017","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"B40","doi-asserted-by":"publisher","first-page":"6065","DOI":"10.1016\/j.vaccine.2019.09.065","article-title":"Changes in serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates from adult patients in Asia: emergence of drug-resistant non-vaccine serotypes","volume":"38","author":"Kim","year":"2020","journal-title":"Vaccine"},{"key":"B41","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.biologicals.2011.05.004","article-title":"Biochemical and biological characteristics of cross-reacting material 197 CRM197, a non-toxic mutant of diphtheria toxin: use as a conjugation protein in vaccines and other potential clinical applications","volume":"39","author":"Br\u00f6ker","year":"2011","journal-title":"Biologicals"},{"key":"B42","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1134\/s106816201206012x","article-title":"Perspectives of application of recombinant diphtheria toxin derivatives","volume":"38","author":"Romaniuk","year":"2012","journal-title":"Bioorg Khim"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e0195799","DOI":"10.1371\/journal.pone.0195799","article-title":"Pneumococcal carriage in children and their household contacts six years after introduction of the 13-valent pneumococcal conjugate vaccine in England","volume":"13","author":"Southern","year":"2018","journal-title":"PLoS One"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/s40121-023-00798-x","article-title":"Historical population-level impact of infant 13-valent pneumococcal conjugate vaccine (PCV13) national immunization programs on invasive pneumococcal disease in Australia, Canada, England and Wales, Israel, and the United States","volume":"12","author":"Perdrizet","year":"2023","journal-title":"Infect Dis Ther"},{"key":"B45","doi-asserted-by":"publisher","first-page":"4813","DOI":"10.1016\/j.vaccine.2015.07.080","article-title":"Impact of the 13-valent pneumococcal conjugate vaccine (pcv13) on invasive pneumococcal disease and carriage in Alaska","volume":"33","author":"Bruce","year":"2015","journal-title":"Vaccine"},{"key":"B46","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3345\/kjp.2014.57.2.55","article-title":"Efficacy and effectiveness of extended-valency pneumococcal conjugate vaccines","volume":"57","author":"Lee","year":"2014","journal-title":"Korean J Pediatr"},{"key":"B47","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s40272-013-0047-z","article-title":"13-valent pneumococcal conjugate vaccine: a review of its use in infants, children, and adolescents","volume":"15","author":"Plosker","year":"2013","journal-title":"Paediatr Drugs"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1272562","DOI":"10.3389\/fpubh.2023.1272562","article-title":"Post-marketing safety surveillance for both CRM197 and TT carrier proteins PCV13 in Jiangsu, China","volume":"11","author":"Hu","year":"2023","journal-title":"Front Public Health"},{"key":"B49","doi-asserted-by":"publisher","first-page":"9596129","DOI":"10.1155\/2020\/9596129","article-title":"The pneumococcal polysaccharide-tetanus toxin native C-fragment conjugate vaccine: the carrier effect and immunogenicity","volume":"2020","author":"Yu","year":"2020","journal-title":"Mediators Inflamm"},{"key":"B50","doi-asserted-by":"publisher","first-page":"870973","DOI":"10.3389\/fmicb.2022.870973","article-title":"Immunogenicity and safety of a novel 13-valent pneumococcal vaccine in healthy Chinese infants and toddlers","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Microbiol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"3816","DOI":"10.1002\/1521-4141(200112)31:12%3C3816::AID-IMMU3816%3E3.0.CO;2-K","article-title":"Rationally designed strings of promiscuous CD4(+) T cell epitopes provide help to haemophilus influenzae type b oligosaccharide: a model for new conjugate vaccines","volume":"31","author":"Falugi","year":"2001","journal-title":"Eur J Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"5835","DOI":"10.1128\/IAI.73.9.5835-5841.2005","article-title":"Combined conjugate vaccines: enhanced immunogenicity with the N19 polyepitope as a carrier protein","volume":"73","author":"Baraldo","year":"2005","journal-title":"Infect Immun"},{"key":"B53","doi-asserted-by":"publisher","first-page":"6947","DOI":"10.1016\/j.vaccine.2021.09.047","article-title":"A phase 3 clinical trial of MINHAI PCV13 in Chinese children aged from 7 months to 5 years old","volume":"39","author":"Liang","year":"2021","journal-title":"Vaccine"},{"key":"B54","doi-asserted-by":"publisher","first-page":"A110","DOI":"10.1016\/j.vaccine.2014.04.079","article-title":"Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian children in the second year of life","volume":"32","author":"Bhandari","year":"2014","journal-title":"Vaccine"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1016\/S0140-6736(13)62630-6","article-title":"Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial","volume":"383","author":"Bhandari","year":"2014","journal-title":"Lancet"},{"key":"B56","doi-asserted-by":"publisher","first-page":"6228","DOI":"10.1016\/j.vaccine.2017.09.014","article-title":"A randomized phase III clinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants","volume":"35","author":"Kulkarni","year":"2017","journal-title":"Vaccine"},{"key":"B57","doi-asserted-by":"publisher","first-page":"A114","DOI":"10.1016\/j.vaccine.2011.07.118","article-title":"A dose-escalation safety and immunogenicity study of a new live attenuated human rotavirus vaccine (rotavin-M1) in Vietnamese children","volume":"30","author":"Dang","year":"2012","journal-title":"Vaccine"},{"key":"B58","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1136\/eb-2014-101793","article-title":"Intussusception risk increased after rotavirus vaccination but outweighed by benefits","volume":"19","author":"Anderson","year":"2014","journal-title":"Evid Based Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1093\/cid\/cit520","article-title":"Intussusception risk and disease prevention associated with rotavirus vaccines in Australia\u2019s national immunization program","volume":"57","author":"Carlin","year":"2013","journal-title":"Clin Infect Dis"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e20161082","DOI":"10.1542\/peds.2016-1082","article-title":"Intussusception rates before and after the Introduction of rotavirus vaccine","volume":"138","author":"Tate","year":"2016","journal-title":"Pediatrics"},{"key":"B61","doi-asserted-by":"publisher","first-page":"CD008521","DOI":"10.1002\/14651858.CD008521.pub6","article-title":"Vaccines for preventing rotavirus diarrhoea: vaccines in use","volume":"11","author":"Bergman","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1086\/340103","article-title":"The role of serum antibodies in the protection against rotavirus disease: an overview","volume":"34","author":"Jiang","year":"2002","journal-title":"Clin Infect Dis"},{"key":"B63","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S1473-3099(20)30001-3","article-title":"Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial","volume":"20","author":"Groome","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"B64","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41598-017-18973-9","article-title":"Inactivated rotavirus vaccine by parenteral administration induces mucosal immunity in mice","volume":"8","author":"Resch","year":"2018","journal-title":"Sci Rep"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1128\/jvi.61.5.1488-1494.1987","article-title":"Synthesis and immunogenicity of the rotavirus major capsid antigen using a baculovirus expression system","volume":"61","author":"Estes","year":"1987","journal-title":"J Virol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0264-410X(98)00319-3","article-title":"Biochemical and immunologic comparison of virus-like particles for a rotavirus subunit vaccine","volume":"17","author":"Madore","year":"1999","journal-title":"Vaccine"},{"key":"B67","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1080\/21645515.2015.1099772","article-title":"Rotavirus capsid VP6 protein acts as an adjuvant in vivo for norovirus virus-like particles in a combination vaccine","volume":"12","author":"Blazevic","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"B68","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S0966-842X(03)00208-7","article-title":"Virus-like particles as immunogens","volume":"11","author":"Noad","year":"2003","journal-title":"Trends Microbiol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1038\/emi.2016.73","article-title":"EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases","volume":"5","author":"Mao","year":"2016","journal-title":"Emerg Microbes Infect"},{"key":"B70","doi-asserted-by":"publisher","first-page":"811553","DOI":"10.3389\/fmicb.2021.811553","article-title":"Surveillance, epidemiology and impact of EV-A71 vaccination on hand, foot, and mouth disease in Nanchang, China, 2010\u20132019","volume":"12","author":"He","year":"2021","journal-title":"Front Microbiol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s12879-020-04992-x","article-title":"Co-circulation of coxsackieviruses A-6, A-10, and A-16 causes hand, foot, and mouth disease in Guangzhou city, China","volume":"20","author":"Xie","year":"2020","journal-title":"BMC Infect Dis"},{"key":"B72","doi-asserted-by":"publisher","first-page":"13357","DOI":"10.1038\/s41598-018-31616-x","article-title":"The emerging sub-genotype C2 of coxsackievirusA10 associated with hand, foot and mouth disease extensively circulating in mainland of China","volume":"8","author":"Ji","year":"2018","journal-title":"Sci Rep"},{"key":"B73","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/jmv.24151","article-title":"Epidemiological and etiological characteristics of hand, foot, and mouth disease in Wuhan, China from 2012 to 2013: outbreaks of coxsackieviruses A10","volume":"87","author":"Yang","year":"2015","journal-title":"J Med Virol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"e0142733","DOI":"10.1371\/journal.pone.0142733","article-title":"Etiology of multiple non-EV71 and non-CVA16 enteroviruses associated with hand, foot and mouth disease in Jinan, China, 2009\u2013June 2013","volume":"10","author":"Guan","year":"2015","journal-title":"PLoS One"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1002\/jmv.24200","article-title":"Characterization of severe hand, foot, and mouth disease in Shenzhen, China, 2009\u20132013","volume":"87","author":"Huang","year":"2015","journal-title":"J Med Virol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1080\/22221751.2022.2125346","article-title":"Molecular epidemiology and clinical features of hand, foot and mouth disease requiring hospitalization after the use of enterovirus A71 inactivated vaccine in Chengdu, China, 2017\u20132022: a descriptive study","volume":"11","author":"Duan","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"B77","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.1016\/j.vaccine.2018.05.005","article-title":"The immunogenicity and protection effect of an inactivated coxsackievirus A6, A10, and A16 vaccine against hand, foot, and mouth disease","volume":"36","author":"Lim","year":"2018","journal-title":"Vaccine"},{"key":"B78","doi-asserted-by":"publisher","first-page":"7095","DOI":"10.1016\/j.vaccine.2018.09.069","article-title":"Characterization of an inactivated whole-virus bivalent vaccine that induces balanced protective immunity against coxsackievirus A6 and A10 in mice","volume":"36","author":"Zhang","year":"2018","journal-title":"Vaccine"},{"key":"B79","doi-asserted-by":"publisher","first-page":"5919","DOI":"10.3390\/v7112916","article-title":"Efficacy of a trivalent hand, foot, and mouth disease vaccine against enterovirus 71 and coxsackieviruses A16 and A6 in mice","volume":"7","author":"Caine","year":"2015","journal-title":"Viruses"},{"key":"B80","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1586\/14760584.6.3.381","article-title":"Virus-like particles: flexible platforms for vaccine development","volume":"6","author":"Chackerian","year":"2007","journal-title":"Expert Rev Vaccines"},{"key":"B81","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.antiviral.2019.02.016","article-title":"Recombinant virus-like particle presenting a newly identified coxsackievirus A10 neutralization epitope induces protective immunity in mice","volume":"164","author":"Dai","year":"2019","journal-title":"Antiviral Res"},{"key":"B82","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1007\/s00705-019-04418-3","article-title":"Intranasal immunization with coxsackievirus A16 virus-like particles confers protection against lethal infection in neonatal mice","volume":"164","author":"Chen","year":"2019","journal-title":"Arch Virol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"4296","DOI":"10.1016\/j.vaccine.2021.06.031","article-title":"Preclinical evaluation of recombinant HFMD vaccine based on enterovirus 71 (EV71) virus-like particles (VLP): immunogenicity, efficacy and toxicology","volume":"39","author":"Wang","year":"2021","journal-title":"Vaccine"},{"key":"B84","doi-asserted-by":"publisher","first-page":"4296","DOI":"10.1016\/j.vaccine.2014.06.025","article-title":"A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice","volume":"32","author":"Ku","year":"2014","journal-title":"Vaccine"},{"key":"B85","doi-asserted-by":"publisher","first-page":"100430","DOI":"10.1016\/j.lanwpc.2022.100430","article-title":"National, regional, and provincial disease burden attributed to Streptococcus pneumoniae and haemophilus influenzae type b in children in China: modelled estimates for 2010\u201317","volume":"22","author":"Lai","year":"2022","journal-title":"Lancet Reg Health West Pac"},{"key":"B86","first-page":"768","article-title":"Community-Acquired pneumonia: determining safe treatment in the outpatient setting","volume":"99","author":"Ebell","year":"2019","journal-title":"Am Fam Physician"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1093\/cid\/ciy743","article-title":"Safety and immunogenicity of pneumococcal conjugate vaccines in a high-risk population: a randomized controlled trial of 10-valent and 13-valent pneumococcal conjugate vaccine in Papua New Guinean infants","volume":"68","author":"Pomat","year":"2019","journal-title":"Clin Infect Dis"},{"key":"B88","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1749-6632.2012.06673.x","article-title":"Development and clinical evaluation of prevnar 13, a 13-valent pneumocococcal CRM197 conjugate vaccine","volume":"1263","author":"Gruber","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"B89","doi-asserted-by":"publisher","first-page":"3428","DOI":"10.1016\/j.vaccine.2021.04.037","article-title":"Immunogenicity and safety of 7-valent pneumococcal conjugate vaccine (PCV7) in children aged 2\u20135 years in China","volume":"39","author":"Wang","year":"2021","journal-title":"Vaccine"},{"key":"B90","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1136\/jech.2010.111880","article-title":"Cost-effectiveness of introducing the 10-valent pneumococcal conjugate vaccine into the universal immunisation of infants in Brazil","volume":"66","author":"Sartori","year":"2012","journal-title":"J Epidemiol Community Health"},{"key":"B91","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.2223\/JPED.1475","article-title":"Impact of pneumococcal conjugate vaccine on the prevention of invasive pneumococcal diseases","volume":"82","author":"Bricks","year":"2006","journal-title":"J Pediatr"},{"key":"B92","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3947\/ic.2016.48.4.257","article-title":"Indirect effects of pneumococcal conjugate vaccines in national immunization programs for children on adult pneumococcal disease","volume":"48","author":"Kim","year":"2016","journal-title":"Infect Chemother"},{"key":"B93","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/14760584.2023.2294153","article-title":"PCV15, a pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in infants and children","volume":"23","author":"Chapman","year":"2024","journal-title":"Expert Rev Vaccines"},{"key":"B94","doi-asserted-by":"publisher","first-page":"106942","DOI":"10.1016\/j.ijid.2024.01.009","article-title":"A phase 3 randomized study to evaluate safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in healthy Japanese infants","volume":"141","author":"Ishihara","year":"2024","journal-title":"Int J Infect Dis"},{"key":"B95","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1097\/INF.0000000000004334","article-title":"A phase three study of the safety and immunogenicity of a four-dose series of 20-valent pneumococcal conjugate vaccine in healthy infants","volume":"43","author":"Senders","year":"2024","journal-title":"Pediatr Infect Dis J"},{"key":"B96","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1016\/j.vaccine.2016.03.107","article-title":"Status of research and development of pediatric vaccines for Streptococcus pneumoniae","volume":"34","author":"Alderson","year":"2016","journal-title":"Vaccine"},{"key":"B97","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1080\/14760584.2019.1627207","article-title":"Relationship between immune response to pneumococcal conjugate vaccines in infants and indirect protection after vaccine implementation","volume":"18","author":"Dagan","year":"2019","journal-title":"Expert Rev Vaccines"},{"key":"B98","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.yapd.2022.03.011","article-title":"Vaccine hesitancy in pediatrics","volume":"69","author":"Lafnitzegger","year":"2022","journal-title":"Adv Pediatr"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1414177\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T04:46:41Z","timestamp":1719982001000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1414177\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,3]]},"references-count":98,"alternative-id":["10.3389\/fped.2024.1414177"],"URL":"https:\/\/doi.org\/10.3389\/fped.2024.1414177","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,3]]},"article-number":"1414177"}}